ORKA
Oruka Therapeutics, Inc.28.94
-1.16-3.85%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.40BP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
8-K
10-Q
Q3 FY2025 results
Oruka Therapeutics posted a Q3 net loss of $30.3 million, up 6% year-over-year from $28.6 million, driven by higher research and development expenses of $29.0 million (up 13%) tied to clinical trial advancements for ORKA-001 and ORKA-002, while general and administrative costs rose 36% to $5.1 million amid team expansion. Operating losses widened to $34.1 million, offset by $3.8 million in interest income, yielding diluted EPS of -$0.55 on 44.1 million shares—consistent with the $30.3 million loss allocation. Cash and equivalents climbed to $91.3 million, with total liquidity at $500.9 million after netting $169.6 million from the September 2025 PIPE financing, supporting runway through at least mid-2027. No debt burdens; free cash flow not disclosed in the 10-Q. Yet competition from established IL-23 and IL-17 inhibitors looms large.
10-Q
Q2 FY2025 results
Oruka Therapeutics posted a Q2 net loss of $24.6M, up 10% y/y from $22.2M, driven by ramped R&D spending on clinical trials for psoriasis candidates ORKA-001 and ORKA-002, while interest income of $3.9M from a $351.5M cash pile softened the blow. Operating expenses climbed 32% y/y to $28.4M, with R&D at $24.1M (up 29%) reflecting higher personnel and stock-based comp costs, yet external R&D dipped 4% as Paragon work eased. Cash burn hit $44.0M YTD, but the balance sheet stays solid with no debt and ample liquidity to fund trials through at least mid-2026. The merger with Pre-Merger Oruka closed in August 2024 for $275M in stock and warrants, recognizing no goodwill as it was a reverse recap. Competition from entrenched IL-23 and IL-17 therapies could squeeze market share if half-life extensions underperform.
8-K
Oruka appoints COO Sandler
Oruka Therapeutics appointed Laura Sandler as Chief Operating Officer on July 1, 2025, promoting her from Senior VP of Operations since March 2024. With deep biopharma experience at CRISPR Therapeutics and bluebird bio, she steps up to oversee clinical execution and development ops. Base salary hits $460,000, plus 40% target bonus and 25,000 stock options vesting over four years. Enhanced severance ties to change in control, accelerating equity fully. Leadership bolsters pipeline momentum.
8-K
Annual meeting results
Oruka Therapeutics held its annual stockholder meeting on June 2, 2025, electing Carl Dambkowski and Peter Harwin as Class I directors until 2028, with strong support of over 25 million shares each. Stockholders ratified PricewaterhouseCoopers as auditors for 2025 and approved executive compensation on an advisory basis. They favored annual say-on-pay votes, which the board adopted. Routine governance wins signal steady investor alignment.
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
OKYO
OKYO Pharma Limited
1.88-0.01
ORGS
Orgenesis, Inc.
0.15-0.01
ORIC
Oric Pharmaceuticals, Inc.
9.12-0.11
ORMP
Oramed Pharmaceuticals Inc.
3.08+0.00
OSTX
OS Therapies Incorporated
1.62-0.05
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
XBIT
XBiotech Inc.
2.45-0.08